EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics
· Proceeds will fund clinical development of oncology and immunology therapeutics derived from innovative antibody payload platform · Mark Throsby, industry veteran and former CSO of Merus, joins as Executive ChairEQT Life Sciences is pleased to announce that its LSP 7 fund has invested in ATB Therapeutics. The €54 million Series A funding round is aimed at accelerating the clinical development of a groundbreaking therapeutic antibody pipeline derived from its proprietary ATBioFarm platform. The financing was co-led by EQT Life Sciences and MRL Ventures Fund (MRLV, a corporate venture